Sangamo BioSciences with $100M secondary

After a 72% run YTD, Sangamo BioSciences (SGMO) decides to raise some capital, offering $100M of new stock with an underwriter greenshoe for 15% of that amount.

Shares -2.2% AH

From other sites
Comments (1)
  • MineMan
    , contributor
    Comments (601) | Send Message
    If nothing else a "buy rec" from JPM is in the future.
    And JPM would NOT sell shares to their preferreed clients if they thought the Price per share would not rise.
    SGMO/Ed Lanphier will use the funds wisely and in a way that is sure to add value to the share price.
    19 Mar 2014, 07:06 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs